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Abstract
The infection from Epstein-Barr virus (EBV) or virus of infectious mononucleosis, together 
with  other  herpes viruses’  infections,  represents  a  prototype  of  persistent  viral  infections 
characterized by the property of the latency. Although the reactivations of the latent infection 
are  associated  with  the  resumption  of  the  viral  replication  and  eventually  with  the 
“shedding”, it is still not clear if this virus can determine chronic infectious diseases, more or 
less evolutive. These diseases could include some pathological conditions actually defined as 
“idiopathic”and characterized by the “viral persistence” as the more credibl
factor.  Among  the  so-called  idiopathic  syndromes,  the  “chronic  fatigue  syndrome”  (CFS) 
aroused a great interest around the eighties of the last century when, just for its relationship 
with EBV, it was called “chronic mononucleosis” or “chron
Today  CFS,  as  defined  in  1994  by  the  CDC  of  Atlanta  (USA),  really  represents  a 
multifactorial syndrome characterized by a chronic course, where reactivation and remission 
phases alternate, and by a good prognosis. The etiopathogenetic r
only in a well-examined subgroup of patients, while in most of the remaining cases this role 
should be played by other infectious agents 
host – or even by not infectious agent
pathogenetic substrate of the different etiologic forms seems to be the same, much probably 
represented by the oxidative damage due to the release of pro
response to the triggering event (infectious or not infectious). 
Anyway, recently the scientists turned their’s attention to the genetic predisposition of the 
subjects affected by the syndrome, so that in the last years the genetic studies, together with 
those  of  molecular  biology, received  a  great impulse.  Thanks to both  these  studies  it was 
possibile to confirm the etiologic links between the syndrome and EBV or other herpesviruses 
or other persistent infectious agents.
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aroused a great interest around the eighties of the last century when, just for its relationship 
with EBV, it was called “chronic mononucleosis” or “chronic EBV infection”. 
Today  CFS,  as  defined  in  1994  by  the  CDC  of  Atlanta  (USA),  really  represents  a 
multifactorial syndrome characterized by a chronic course, where reactivation and remission 
phases alternate, and by a good prognosis. The etiopathogenetic role of EBV is demonstrated 
examined subgroup of patients, while in most of the remaining cases this role 
should be played by other infectious agents - able to remain in a latent or persistent way in the 
or even by not infectious agents (toxic, neuroendocrine, methabolic, etc.). However, the 
pathogenetic substrate of the different etiologic forms seems to be the same, much probably 
represented by the oxidative damage due to the release of pro-inflammatory cytokines as a 
triggering event (infectious or not infectious). 
Anyway, recently the scientists turned their’s attention to the genetic predisposition of the 
subjects affected by the syndrome, so that in the last years the genetic studies, together with 
molecular  biology, received  a great impulse.  Thanks to both  these  studies  it was 
possibile to confirm the etiologic links between the syndrome and EBV or other herpesviruses 
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The mechanisms of EBV latency have been carefully examined both because they represent 
the virus strategy to elude the response of the immune system of the host, and because they 
are correlated with those oncologic conditions associated to the viral persistence, particularly 
lymphomas  and  lymphoproliferative  disorders.  Just  these  malignancies,  for  which  a 
pathogenetic role of EBV is clearly documented, should represent the main clinical expression 
of  a  first  group  of  chronic  EBV  infections  characterized  by  a  natural  history  where  the 
neoplastic event aroused from the viral persistence in the resting B cells for all the life, from 
the genetic predisposition of the host and from the oncogenic potentialities of the virus that 
chronically persists and incurs reactivations. 
Really,  these  oncological  diseases  should  be  considered  more  complications  than  chronic 
forms of the illness, as well as other malignancies for which a viral – or even infectious -
etiology is well recognized. The chronic diseases, in fact, should be linked in a pathogenetic 
and temporal way to the acute infection, from whom start the natural history of the following 
disease. So, as for the chronic liver diseases from HBV and HCV, it was conied the acronym 
of CAEBV (Chronic Active EBV infection), distinguishing within these pathologies the more 
severe forms (SCAEBV) mostly  reported  in Far  East  and among children  or adolescents. 
Probably  only  these  forms  have  to  be  considered  expressions  of  a chronic  EBV  infection 
“sensu scrictu”, together with those forms of CFS where the etiopathogenetic and temporal 
link  with  the  acute  EBV  infection  is  well  documented.  As  for  CFS,  also  for  CAEBV  the 
criteria for a case definition were defined, even on the basis of serological and virological 
findings.  However,  the  lymphoproliferative  disorders  are  excluded  from  these  forms  and 
mantain  their  nosographic  (e.g.  T  or  B  cell  or  NK  type  lymphomas)  and  pathogenetic 
collocation, even when they occur within chronic forms of EBV infection. In the pathogenesis, 
near  to  the  programs  of  latency  of  the  virus,  the  genetic  and  environmental  factors, 
independent from the real natural history of EBV infection, play a crucial role. 
Finally, it was realized a review of cases - not much numerous in literature – of chronic EBV 
infection associated to chronic liver and neurological diseases, where the modern techniques 
of molecular biology should be useful to obtain a more exact etiologic definition, not always 
possibile to reach in the past.
The wide variety of clinical forms associated to the EBV chronic infection makes difficult the 
finding  of  a  univocal  pathogenetic  link.  There  is  no  doubt,  however,  that  a  careful 
examination of the different clinical forms described in this review should be useful to open 
new  horizons  to  the  study  of  the  persistent  viral  infections  and  the  still  not  well  cleared 
pathologies that they can induce in the human host. 
Introduction:  “Once  infected,  always  infected”.
Introduced in order to express in synthetic way the 
pathogenetic  essence  of  the  infection  from 
Cytomegalovirus, whose natural history constitutes 
one of the more classic examples of persistence of 
an  infectious  agent  in  the  human  organism,  this 
maxim  can  be  applied  to  an  always  increasing 
number  of  infections,  both  viral  and  not.  The 
concept  that  it  synthetizes  represents  one  of  the 
more  interesting  and  innovative  aspects  of  the 
modern infectivology. This one is more and more 
very  rarely  represented  from  acute  infectious 
diseases that can effectively be resolved with anti-
infectives  drugs  and  by  now  be  prevented  with 
vaccines. The persistent and/or chronic infections -
in  which  the  microorganism  does  not  come 
eliminated  from  the  host  but  persists  for  months,
years or even all the life - emerge instead, and they 
end with prevailing. This happens for the conditions 
of immunodeficiency of the host whose immunity 
answer is not able to eliminate the infectious agent, 
even  if  can  partially  slow  down  the  pathogenic 
action.  Furthermore,  it  also  depends  from  the 
biological  characteristics  of  the  virus  that 
determines  its  persistence  (through  the  latency  or 
the fast mutation towards less virulent forms able to 
persist more over a long time or even indefinitely in 
the host, without necessarily cause a damage).
In the within of the persistent viral infections it 
is important to distinguish those in which there are 
an active replication and release of the virus for a 
long period of time and where the virus can be often Medit J Hemat Infect Dis 2010; 2(1): Open Journal System
cultivated or identified (e.g.: through the techniques 
of molecular biology), that we can properly indicate 
as chronic viral infections. There are then the latent 
viral infections in which the virus persists in a form 
unable to be identified through standard methods as 
the coltural exams or electronic microscopy; neither 
the  latency  can  be  revealed  from  the  immune 
system  of  the  host.  At  worst  this  last  one  can 
evidence the “reactivation” of the latent infection, 
when it occurs. It involves the production of new
virions and eventually the “shedding” of complete 
viral  particles.  This  means  that  throughout  the 
latency  the  viral  genome  must  be  present  all 
complete: the more important mechanism through 
which  this  happens,  but  sure  not  the  only,  is  the 
integration of the viral genome in that one of the 
cell host (e.g.: infection from hepatitis B virus or 
HBV).
1,2,3,4
Among  the  persistent  viral  infections 
characterized from the latency those supported from 
the family of Herpesviridae are above all. In this 
kind  of  infections  the  reactivation  can  be 
accompanied  to  a  resumption  of  the  viral 
replication, and eventually to the “shedding”, but it 
is  discussed  if  it  can  induce  chronic  infectious 
diseases, more or less evolutive.  
This  is  particularly  true  for  the  Epstein-Barr
virus (EBV)  or  virus  of  the  infectious 
mononucleosis  (IM),  sure  endowed,  like  all  the 
herpetic viruses, of the property of latency and like 
such it is sure implied in the pathogenesis of several 
onco-haematological diseases. It is less clear instead 
if forms of EBV chronic infection able to induce 
evolutive pathologies can exist, like for the hepatitis 
B or C, through eventually the more or less frequent 
reactivation of the latent infection.
The search of possible chronic forms of EBV 
infection must not consider only eventual persistent 
mononucleosis syndromes that of it would represent 
the natural clinico-pathogenetical equivalent as well 
as  the  lymphoproliferative  forms  for  which  the 
correlation with the virus at this point is definitively 
established.  It is  necessary  in  fact  to  address  to 
some pathological conditions currently defined like 
“idiopathic” for which the phenomenon of the “viral 
persistence”  seems  to  represent  the  more  reliable 
pathogenetic element.
5
Between  these  pathologies  we  could  mention 
diseases  like  rheumatoid  arthritis,  systemic 
erythematous lupus, multiple sclerosis and above all 
the “chronic fatigue syndrome” in which a role of 
EBV  still  remains  controversial  and  of  difficult 
demonstration,  even  though  many  Authors 
hypothesized a direct or indirect role of such virus.
6
EBV and diseases
Virologic  features  and  acute  or  persistent 
infection:  Epstein-Barr  virus  (EBV)  belongs  to 
Herpesviridae family,  which  includes  various 
viruses that have co-evoluted with their respective 
hosts  over millions  of  years  and  during  this  time 
have developed sophisticated strategies for lifelong 
persistence that are beneficial for their survival and 
spread.
7
The structure  of  EBV  shows  a linear  double-
stranded  DNA,  an  icosadeltahedral  capside,  162 
capsomers  and  an  envelope.  The  EBV  genoma 
encodes  nearly  100  viral  proteins.
8 During  viral 
replication, these proteins play a fundamental role 
in  regulating  the  expression of  viral  genes, 
replicating  viral  DNA,  forming  structural 
components of the virion, and modulating the host 
immune response.
The receptor for the virus on epithelial cells and 
B  lymphocytes  is  the  CD21  molecule,  formerly 
called CR2, which is also the receptor for the C3d 
component of complement.
9In vitro the infection of 
B  lymphocytes  by  EBV  determines  a  continuous 
cell  proliferation,  which  results  in  a  cellular 
immortalisation;  the  infection  of  epithelial  cells, 
instead,  results  in  an  active  replication, with 
production of virions and host cell lysis.
10 In vivo 
there are other factors in addition to CD21 that are 
important  to  determine  the  infection.  The  major 
histocompatibility  complex  (MHC)  class  II 
molecule serves as cofactor for the infection of B 
cells.
11
Cellular  infection  from  EBV  could  have  two 
possible outcomes. A lytic infection occurs wherein 
virions are produced and the host cell is lysed. Lytic 
infection  tipically  occurs  in  epithelial  cells  and 
partly  in  plasma  cells.
12 Alternatively,  EBV  may 
induce a latent infection by generating an episome, 
the  circular  EBV  genoma,  that  is  located  in  the 
nucleus of host lymphocytes. This episome remains 
in  a  latent  form  in  B  cells;
13 viral  replication  is 
spontaneously activated in only a small percentage 
of  latently infected B cells.
Infection of humans from EBV usually follows 
the  contact  with  oral  secretions.  The  viral 
replication occurs in cells  of  the oropharynx, and 
nearly all seropositive persons actively shed virus in 
the  saliva.  Although  earlier  studies  indicated  that 
the  virus  replicated  in  epithelial  cells  of  the 
oropharynx,
10 and  investigators  postulated  that  B 
cells were subsequently infected after contact with 
these  cells,  other  studies  suggest  that  B  cells  in 
oropharynx may be the primary site of infection.
14
Primary  infection in  young  children  usuallyMedit J Hemat Infect Dis 2010; 2(1): Open Journal System
Table 1. EBV latent viral genes (from Crawford DH
7).
GENE GENE PRODUCT POSTULATED FUNCTION
BKRF1 EBNA-1
viral genome maintenance
essential for in vitro immortalization of B cells 
BYRF1 EBNA-2
viral oncogene
essential for in vitro B-cells immortalization
BLF3-BERF1 EBNA-3A essential for in vitro B-cell immortalization
BERF2-BERF2 EBNA-3B not known
BERF3-BERF4 EBNA-3C viral oncogene
essential for in vitro B-cell immortalization
BWRF1 EBNA-LP not known
BNLF1 LMP-1 induces lymphoblastoid phenotype
tumor necrosis factor receptor superfamily member
BARF1/BNRF1 LMP-2A prevents cell activation and lytic-cycle entry
BNRF1 LMP-2B not known
BCRF1 EBER1, EBER2 regulates PKCactivity
upregulates bcl2 on Burkitt’s lymphoma cells
BARF0 BamHIA transcripts not known
Abbreviations: EBNA: Epstein-Barr viral nuclear antigen; LMP-1: Latent membrane protein; EBER: Epstein-Barr viral small RNA; 
PKC: Protein kinase C. 
occurs  in  an  asymptomatic  way  but,  in  50%  of 
adolescents,  it  causes  infectious  mononucleosis 
(IM). In healthy individuals, the primary infection 
comes  to  a  resolution  and  the  virus  establishes  a 
harmless latent, persistent infection.
IM  usually  presents  with  the  acute  onset  of 
fever, sore throat and enlarged and painful lymph 
glands  in  the  neck.  However,  the  more  typical 
clinical  feature  of  the  disease,  in  a  position  to 
distinguish it from other viral and bacterial throat 
infections,  is  represented  by  a  severe  and 
debilitating  fatigue  which  accompanies    these 
symptoms and which may last for months after they 
have resolved.
Primary  EBV  infection  induces  both  humoral 
and cellular immune response that  control  but  do 
not  eliminate  the  infection.  Antibodies  are 
generated  to  both  latent  and  lytic  antigens,  and 
those directed against the virus receptor on the viral 
envelope,  glycoprotein  350  (gp350),  prevent 
binding to CR2 on B cells and thereby limit viral 
spread and prevent reinfection.
7
Immunoglobulin M antibodies to the EBV viral 
capside  antigen  (anti-VCA)  evolve  quickly  with 
infection, persist for weeks to months, and do not 
reappear.  Thus,  their  detection  is  presumptive 
evidence of recent primary infection. IgG anti-VCA 
shows  a  rise,  a  subsequent  fall,  and  a  lifelong 
persistence  usually  in  titers  ranging  from  1:40  to 
1:2560.  Antibodies  to  viral  early  (pre-DNA 
synthesis) antigens (anti-EA) of the diffuse (D) or 
restricted  (R)  types  develop  in  most  primary 
infections, peak  in  titers  of  less  than  1:640,  and 
wane with time. Antibody to EBV nuclear antigen 
(anti-EBNA)  are  detected  in  traditional  assay 
relatively late after the onset of symptoms in IM, so 
that  their  absence  in  previously  well  person  who 
develops  acute  illness  suggest  an  ongoing  EBV 
infection.
15
The  response  of  CD8-positive  (CD8+) 
cytotoxic T-cells is crucial  to control the primary 
infection, and these cells show a predominant role 
in IM, being present in the circulation and tissues in 
very high numbers. These cells probably give rise to 
most of the symptoms and signs of IM as a result of 
massive  production  of  cytokines,  including 
lymphotoxin,  tumor  necrosis  factor-,  interleukin 
(IL)-1 and IL-6.
16
That  CD8+  T  cells  are  essential  for  recovery 
from  IM  is  exemplified  by  the  consequence  of 
primary  EBV  infection  in  immunocompromised 
individuals who are unable to mount the appropriate 
response and who usually die of a fulminating IM-
like syndrome within weeks of acquiring EBV. This 
is  the  case  of  childrens  affected  by  the  X-linked 
lymphoproliferative syndrome (XLPS), where some 
of them, survived to the initial infection, develop in 
a  second  time a  B-cell  lymphoma  and/or 
dysgammaglobulinemia. 
As  previously  reported,  after  the  primary 
infection  the  virus  persists  in  the  latent  episomal 
form in the nucleus of B lymphocytes and B-cell-
resting.
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Table 2.  Expression of EBV latent genes in disease (from Cohen 
13)*.
PATTERN
OF
LATENCY
EBNA-1 EBNA-2 EBNA-3 LMP-1 LMP-2 EBER DISEASE
Type 1 +     + Burkitt’s lymphoma
Type 2 +   + + +
Nasopharyngeal 
carcinoma, Hodgkin’s 
disease, peripheral T-cell 
lymphoma
Type 3 + + + + + +
Lymphoproliferative 
disease, X-linked 
lymphoproliferative 
disease Infectious 
mononucleosis
Other ±    + + Healthy carrier
Abbreviations: EBNA: Epstein-Barr viral nuclear antigen; LMP: Latent membrane protein; EBER: Epstein-Barr virus encoder RNA. 
*A plus sign indicates that the gene is expressed in the disease, a minus sign that is not expressed, and the two together that the gene 
may or not be expressed
Resting  memory  B  cells  represent  the  site  of 
persistence of  EBV  within  the  body.
17 In  normal 
adults,  from  1  to  50  B  cells  per  million  in  the 
circulation are infected with EBV, and the number 
of  latently  infected  cells  within  a  person  remains 
stable over years.
Of the nearly 100 viral genes that are expressed 
during replication, only 10 are expressed in latently 
infected B cells in vitro: two types of nontranslated 
RNA,  six  nuclear  protein  and  two  membrane
proteins.
By  markedly  limiting  viral  gene  expression 
during  latency, EBV  reduces the  number of  viral 
proteins that permit the recognition of infected cells 
by  cytotoxic  T  cells.  Our  knowledge  of  the 
functions  of  the  latent  proteins  is  extensive  but 
incomplete  (Table  1):  the  main  functions  so  far 
explored  are  represented  by  the  maintenance  of 
latency, the immortalization of B cells in vitro and 
the oncogenetic activity.
Analysing  EBV  gene  expression  in  B-cells 
subsets from peripheral blood and tonsil, Thorley-
Lawson and Babcock
18 suggest that latent infections 
can  be  further  subdivided  into  four  infection 
programs (Table 2). In the first form, only EBNA-1 
and  EBER  are  expressed,  whereas  in  the  second 
form  EBNA-1,  LMP-1,  LMP-2,  and  EBER  are 
expressed. In the third pattern, all the latency genes 
are expressed. A fourth pattern of latency is seen in 
B  cells  obtained  from  the  peripheral  blood  of 
healthy persons infected with EBV in the past, in 
which only EBER and LMP-2, and in some studies, 
EBNA-1 RNA have been detected.
19
Malignancies  associated  with  latent  and/or 
persistent  infection  by  EBV:  The  different 
programs of EBV latency, whose existence should 
be the result of a deliberate strategy of the virus to 
survive to the immunological response of the host, 
have  allowed  to  correlate  some  of  them  with 
malignancies  typically  associated  with  viral 
persistence (Table 2). 
In these pathological conditions the latency of 
EBV is often accompanied by low level, continuous 
or intermittent production of infectious virions into 
the  saliva.
20 So  Burkitt's  lymphoma  should  be 
characterized by the type 1 of the latency program, 
the  nasopharyngeal  carcinoma,  Hodgkin's 
lymphoma and peripheral T cell lymphoma by the 
type 2. The type 3 of the latency program should 
characterize  XLPS  and  other  lymphoproliferative 
diseases induced by EBV in immunocompromised 
hosts  (bone marrow  and solid  organ transplanted, 
etc.), as well as the IM (Table 2).
13
We will not go into the merits of the pathogenic 
mechanisms by which latent EBV infection induces 
lymphoproliferative disease and other malignancies 
with  which  it  was  related,  even  because  this 
argument was recently treated in others reviews of 
this  journal.
21,22,23,24,25 However,  it  is  well 
established  that  these  mechanisms  involve 
virological  factors  associated  with  EBV  antigenic 
characteristics, host factors with particular regard to 
the genetic and immune systems and environmental 
co-factors (see for example the malaria in Burkitt's 
lymphoma and the consumption of "salade fish" in 
nasopharyngeal  carcinoma).  There  is  no  doubt, 
moreover,  that  precisely  these  malignancies,  for 
which  the  pathogenetic  role  of  EBV  has  been Medit J Hemat Infect Dis 2010; 2(1): Open Journal System
Table 3. EBV chronic infection and associated clinical syndromes (adapted from Okano 
41).
CATEGORY
CHARACTERISTICS OF:
CFS CAEBV SCAEBV
Major clinical 
manifestation
Often debilitating fatigue and 
fever
Fever, lymphoadenopathy and 
fatigue (onset begins with acute 
IM)
See CAEBV
             +
hepatosplenomegaly (severe) 
and a tendency for pancytopenia
Age distribution Mostly adults Mostly adults Mostly children
(< 15 years)
Antibody titers to 
EBV
Normal, seropositive or 
seronegative
Reactivation with moderately 
high antibody titers of VCA IgG 
and EA IgG and with low 
antibody titers to EBNA
Extremely high antibody titers of 
VCA IgG (> 5,120) and EA (≥ 
640) and positivity for VCA IgA 
and EA IgA
EBV-DNA with PCR ± +
(high viral load)
++
(very high viral load)
Other designations 
or acronyms in the 
literature
Chronic symptomatic EBV 
infection, chronic 
mononucleosis, chronic acitve 
EBV infection (CAEBV), 
chronic fatigue and immune 
dysfunction syndrome (CFIDS)
CFS, chronic symptomatic EBV 
infection, CAEBV, chronic 
mononucleosis
CAEBV
Abbreviations: CFS: chronic fatigue syndrome; CEBV: chronic active EBV infection; SCAEBV: severe chronic active EBV 
infection.
conclusively  shown,  may  represent  the  clinical 
expression  of  a  first  group  of  EBV  chronic 
infections  in  which  the  natural  history  sees  the 
neoplastic  event,  albeit  conditioned  by  numerous 
other  factors,  not  only  as  the  result  of  the 
persistence  of  EBV  in  resting  B-cells  throughout 
life (so the host is exposed to potentially oncogenic 
viral gene products for a long period of time), but 
also  as  the  result  of  the  virus  ability  to  encode 
grown  promoting  genes,  such  as  EBNA-2  and 
LMP-1, and of the reactivation of a latent infection.
6
Chronic EBV Infection “sensu strictu”
The  term  "chronic  EBV  infection"  should  be 
really referred to the possible chronic evolution of 
clinical  pictures  associated  to  primary  EBV 
infection, symptomatic or asymptomatic, while the 
EBV-associated  neoplastic  diseases,  at  least 
momentarily,  must  be  excluded.  The  clinical 
evolution of these forms over time would determine 
the discharge of the classical features of the EBV 
infection and the assumption of the typical features 
of real complications.
Although  symptoms  associated  with  the  EBV 
acute  illness  (IM)  typically  resolve  in  the  first 
month, a prolonged recovery period associated with 
clinical and laboratory sequelae has been reported 
in the medical literature.
26,27,28 An early description 
of  “chronic  mononucleosis  syndrome”  cited 
“weakness,  aching  legs,  low-grade  fever,  and 
depression” as typical symptoms.
29
However,  it  was  only  in  the  mid  80s  of  last 
century  that  the  problem  of  "chronic 
mononucleosis"  or  chronic  EBV  infection  has 
captured  the  attention  of  researchers,  following  a 
series of clinical studies that have described cohorts 
of  patients  with  prolonged  atipical  illness  with 
persistent  fatigue,  headaches,  myalgia, 
lymphadenopathy,  and  intermittent  and/or  low-
grade  fever.
30,31,32,33,34,35,36 Unexpectedly,  unusual 
profiles of antibodies to EBV were common in this 
syndrome.  Significantly,  the  titers  of  EBV  IgG 
antibodies  to  VCA  and  EA  were  substantially 
higher in patients than in controls.
Because of these serologic patterns and clinical 
symptoms, it was proposed that the syndrome arose 
from a chronic EBV infection.
37
Hellman  et  al.
38 first  proposed  the  acronym 
CAEBV (= Chronic Active EBV infection) for this 
enigmatic disease that, however, seemed to have a Medit J Hemat Infect Dis 2010; 2(1): Open Journal System
good prognosis despite some reports, of Virelizier 
et al.
39 first and Joncas et al.
40  later, about forms of 
CAEBV  characterized  by  more  severe  and  often 
fatal clinical manifestations (SCAEBV). Since the 
first  reports  of  this  new  emerging  syndrome 
potentially  related  to  EBV,  the  NIH  in  Bethesda 
(USA) took on a task to coordinate a study group 
that  in  April  1985  reported  the  preliminary 
findigs
33,34 in  a  workshop  during  which  the 
investigators divided the examined patients into 3 
groups, mainly by EBV serologic results. The first 
group  consisted  of  rare  persons  with  specific 
lymphoproliferative, hypoplastic or other disorders, 
with  some  degree  of  demonstrable  immune 
impairment  and  extraordinarily  elevated  titers  of 
antibodies  to  EBV-related  antigens:  IgG  antibody 
titers to VCA of ≥ 5,120 and to EA diffuse [D] or 
restricted  [R]  of  ≥  640,  and  with  low  or  absent 
antibody titers to EBV-determined nuclear antigen 
(EBNA). The second group included a much larger 
number  of  patients  with  chronic  fatigue,  with  no 
obvious  immunodeficiency,  and  with  variable  but 
less impressive or normal EBV antibody titers. This 
group  was  further  subdivided  as  to  whether  the 
patients had  experienced  an episode  of  acute IM. 
The  third,  small  group  of  patients  included  those 
who  could  not  be  clinically  distinguished  from 
others  with  chronic  fatigue  but  who  lacked  all 
antibodies to EBV.
At this point it became clear that clinical studies 
about this mysterious syndrome, characterized by a 
severe asthenia and marked fatiguability, as well as 
by many other clinical symptoms well explained by 
a persistent EBV infection, have begun to divide, so 
that a division of patients into different groups,
41not 
all  necessarily  linked  to  chronic  EBV  infection 
alone (Table 3), was proposed, and namely:
1)  Chronic  Fatigue  Syndrome  of  unknown 
etiology (CFS)
2)  Chronic Active EBV infection (CAEBV)
3)  Severe  Chronic  Active  EBV  infection 
(SCAEBV).
We will return later on CFS, which is mainly 
characterized by debilitating fatigue, so to discuss 
the  possible  pathogenetic  role  of  EBV,  since this 
syndrome  seems  a  multifactorial  disease  with  a 
pathogenesis still not well defined.
Therefore,  at  the  moment  we  will  take  into 
consideration  only  the  forms  of  chronic  EBV 
infection in which the etiopathogenetic relationship 
with  the  virus  is  demonstrated  by  reliable 
virological and/or immunological studies. Probably, 
the  meaning  of  illness  caused  by  chronic  active 
EBV  infection  "sensu  strictu"  can  be  correctly 
attributed only to these clinical forms.
a) Chronic Active EBV infection (CAEBV): An 
high  titer  of  anti-VCA  antibodies  for  EBV,  the 
frequent presence of IgA and IgM anti-VCA with 
persistently high levels of anti-EA (D) and/or EA 
(R), and occasionally the positivity of IgA anti-EA 
(D)  represent  some  of  the  major  viro-
immunological  characteristics  of  patients  affected 
by  CAEBV.  Some  patients  also  lack  anti-EBNA 
antibodies  which  usually  represent  a  specific 
immune response to EBV infection (Table 3). More 
recently  the  identification  of  EBV-DNA  in 
peripheral  blood  mononuclear  cells  (PBMCs)  and 
tissues  show  an  higher  diagnostic 
significance.
42,43,44,45
The largest group of patients characterized by 
chronic or recurrent infectious mononucleosis-like 
symptoms  persisting  over  a  long  time  and  by 
unusual  pattern  of  anti-EBV  antibodies
37 is 
probably  represented  by  forms  of  CAEBV  CFS-
like. Patients with this syndrome do not show any 
prior immunologic abnormalities or any other sign 
of  a  recent  infection  that  might  explain  their 
condition.
36
There  are  then  the  more  severe  forms  of 
CAEBV  described  mainly  but  not  exclusively  in 
Japan.
46,42,47,41,48,49,50 They are often characterized by 
an unfavourable prognosis because of hematologic, 
gastroenteric,  neurological,  pulmonary,  ocular, 
dermatological  and/or  cardiovascular 
complications.
The  more  interesting  cardiovascular  disorders 
of  patients  with  CAEBV  are  represented  by 
aneurysms  of  the  coronaries  and  valve 
abnormalities.
51 Moreover,  in  the  course  of  the 
disease,  lymphoproliferative  disorders  like 
hemophagocytic  lymphohistiocytosis, 
lymphoproliferative  diseases  and  T  or  NK  cell 
lymphomas  or  various  kind  of  cutaneous 
manifestations (including hydroa vacciniforme), in 
addition  to  hypersensitivity  to  insect  bites,  may 
occur. 
The  large  number  of  studies  by  Japanese 
authors
52,53,54 has identified criteria to highlight the 
differences  that  undoubtedly  exist  between  such 
clinically  heterogeneous  patients,  where  the  only 
link seems to be the correlation with chronic EBV 
infection,  as  demonstrated  by  the  previously 
reported peculiar sero-immunological aspects. 
The  three  main  criteria  of  CAEBV  infection 
were  established  by  Straus
36 and  subsequently 
Okano et al.
55,52 have proposed similar criteria even 
for the most severe form of CAEBV (Table 4 and 
5). Importantly, there are many cases  that do not 
satisfy the criteria described above. Medit J Hemat Infect Dis 2010; 2(1): Open Journal System
Table 4. Proposed guidelines for diagnosing CAEBV* (from Okano 
52).
(1) Persistent or recurrent IM-like symptom
(2) Unusual pattern of anti-EBV antibodies with raised anti-VCA and anti-EA, and/or detection of increased EBV genomes in 
affected tissues, including the peripheral blood
(3) Chronic illness which cannot be explained by other known disease processes at diagnosis 
†
Abbreviations: CAEBV: chronic active Epstein-Barr virus infection; IM: infectious mononucleosis; VCA: viral capsid antigen; EA: 
early antigen; LPD: lymphoproliferative disorder. * A case of CAEBV must fulfill each category. 
† An EBV- associated disease such 
as hemophagocitic lymphohistiocytosis or LPD/lymphoma mainly derived from T-cell or NK-cell lineage often develops during the 
course of illness; some patients also suffer from cutaneous lesions, such as hypersensitivity to mosquito bites.
Some patients lack abnormal patterns of EBV-
related  antibodies,  whereas  other  patients  lack 
major  organ  involvement  or  show  only  skin 
symptoms,  such  as  hypersensitivity  to  mosquito 
bites 
56,57.
On the other hand, Kimura et al.
43  and Maeda 
et  al.
44  have  reported    in  patients  with  CAEBV 
infection extremely high viral loads, as assessed by 
quantitative  polymerase  chain  reaction  (PCR). 
Furthermore, the disease severity directly correlates 
with levels of EBV-DNA in serum or plasma.
58 In 
addition,  there  are  more  and  more  observations 
suggesting that clonal expansion of EBV-infected T 
or  NK  cells  could  be  associated  with  CAEBV 
infection.
59,42,60,47,61,56,62,53,54
Recently,  a  pediatric  survey  of  CAEBV  has 
been  described  also  in  China
63,  even  though  the 
death  rate  was  less  significant  (26,2%)  than  that 
reported in Japan (43-61,5%).
A review of the criteria for CAEBV infection 
appears  to  be  necessary,  based  on  these  recents 
findings.  Okano  et  al.
52  started  this  review.  This 
Author,  even  proposing  again  the  definition  of 
"CAEBV  infection",  with  some  variations 
previously  advanced  by  himself,
41 highlights  the 
persistent  confusion  in  making  such  diagnosis, 
particularly  of  the  more  severe  forms  because  of 
verying  clinical  manifestations,  outcomes,  and 
association with certain underlying diseases, mainly 
LPD derived from T cell or NK-cell lineages. 
Table 5. Supplemental findings and recommended specific laboratory tests for diagnosing CAEBV (from Okano 
52).
1) IM-like  symptoms  generally  include  fever,  swelling  of  lymph  nodes,  and  hepatosplenomegaly;  additional 
complications  include  hematological,  digestive  tract,  neurological,  pulmonary,  ocular,  dermal  and/or  cardiovascular 
disorders (including aneurysm and valvular disease) that mostly have been reported in patients with IM
2) Anti-EBV antibodies with raised anti-VCA and anti-EA ordinarily consist of VCA-IgG ≥ 1:640 and EA-IgG ≥ 
1:160; positive IgA antibodies to VCA and/or EA are often demonstrated
3) Recommended specific laboratory tests
(a) Detection  of  EBV-DNA,  RNA,  related  antigens  and  clonality  in  affected  tissue  including  the 
peripheral blood
i. PCR (quantitative, qualitative)
More than 10 
2,5 copies /g DNA are generally detected in peripheral blood mononuclear cells; 
healthy individuals occasionally show positive results by qualitative PCR analysis
ii. In situ hybridization (e.g., EBERs)
iii. Immunofluorescence etc. (e.g., EBNA, LMP)
iv. Southern blotting (including clonality of EBV)
v. Clarifyng a target cells of EBV infection
Double staining of EBNA or detection of EBER or EBV DNA with each marker for B, T, NK, cells 
or monocytes/ macrophage/ histiocytes is recommended by using such methods as 
immunofluorescence, immunohistological staining, or magnetic beads
(b) Histopatological and molecular evaluation 
i. General histopathology
ii. Immunohistological staining
iii. Chromosomal analysis
iv. Rearrangement studies (e.g., immunoglobulin, T-cell receptor)
(c) Immunological studies
i. Generalized immunological studies
ii. Marker analysis of peripheral blood (including HLA-DR)
iii. Cytokine analysis
Abbreviations: IM: infectious mononucleosis; VCA: viral capsid antigen; EA: early antigen; PCR: polymerase chain reaction; 
EBERs: EBV-encoded RNAs; EBNA: EBV-determined nuclear antigen; LMP: latent membrane protein; HLA: human leukocyte 
antigen.Medit J Hemat Infect Dis 2010; 2(1): Open Journal System
Table 6. Centers for Disease Control’s case definition of the chronic fatigue syndrome (CFS) (from Klonoff  
73)*.
Major Criteria
1. New onset of fatigue lasting 6 months reducing activity to < 50%
2. Other conditions producing fatigue must be ruled out
Minor Criteria
Symptom Criteria – beginning at or after onset of fatigue and persisting or recurring for at least 6 months
1. Low-grade fever: temperature of 37,5°C-38,6°C (99,5°F-101,5°F) orally or chills
2. Sore throat
3. Painful cervical or axillary limph nodes
4. Generalized muscle weakness
5. Muscle pain
6. Postexertional fatigue lasting 24 hours
7. Headache
8. Migratory arthralgias
9. Nueropsychological complaints (photophobia, transient visual scotoma, forgetfulness, excessive irritabilitity, 
confusion, difficulty thinking, inability to concentrate or depression)
10. Sleep disturbance
11. Acute onset of symptoms over a few hours to a few days
Physical Criteria – documented by a phisician twice, at least 1 month apart 
1. Low-grade fever: temperature of 37,6°C-38,6°C (99,7°F-101,5°F) orally or 37,8-38,8°C (100,0°F-101,8°F) 
rectally
2. Nonexudative pharyngitis
3. Palpable cervical or axillary lymph nodes up to 2 cm in diameter
* A case of CFS must fulfill both major criteria as well as reither eight symptom criteria or six symptom criteria plus two physical 
criteria.
So, he proposed the diagnostic criteria by which 
underlying diseases should be accurately diagnosed, 
and  when  the  associated  disease  is  defined,  the 
name of  each  disease  should  be  used  rather  than 
"CAEBV”.  The  latter  term  should  refer  only  to 
cases without an underlying disease at the time of 
diagnosis. 
This  type  of  review  inevitably  leads  to  a 
reduction of chronic forms of EBV infection, most 
of  which  could  be  considered  "chronic  EBV-
associated  lymphoproliferative  disorders"  rather 
than "chronic EBV infections”. Anyway, their study 
first  of  all  demonstrated  that  these  forms  are 
characterized  by  a  clonal  expansion  of  T  or  NK 
cells infected by EBV. Secondly, it was shown that 
this result is made possible by the fact that EBV-
infected T and NK cells express only EB nuclear 
antigen  1  and  latent  membrane  protein  1  (latent 
infection type 2). Since these two proteins are less 
antigenic,  infected  cells  can  escape  the 
immunosurveillance  by  cytotoxic  T  lymphocytes. 
Therefore  they  may  proliferate and  cause  chronic 
infection.
49
There  are  several  noteworthy  differences 
between  the  T- and  NK-cell  types  of  CAEBV 
infection. T-cell type of the disease is characterized 
by fever and high titers of EBV-related antibodies, 
whereas hypersensitivity to mosquito bites and high 
titers of IgE are observed in patients with the NK-
cell type of CAEBV infection.
49 Cell type infection 
is important also in predicting the related prognosis, 
because the survival rates are different between the 
two groups: T-cells type of CAEBV infection has 
shorter survival times than those with NK-cell type 
of infection.
49
In  healthy  carriers  of  EBV,  the  virus  exists 
latently  in  resting  memory  B  cell.
13 It  is  unclear 
whether the invasion of  blood  cells others that  B 
cell causes CAEBV infection or the invasion is an 
ordinary  event,  but  the  host’s  immunologic 
abnormalities  allow  the  expansion  of  these  cells. 
Answering  these  questions  may  have  important 
consequences on our knowledge in relation to other 
forms  of  chronic  EBV  infection  which  are  not 
presently known in their exact entity and frequency. 
There is no doubt that the possibility to search 
for EBV-DNA in PBMCs, plasma, and especially in 
tissues should allow to a better investigation of the 
still  confused  diagnostic  process  of  the  so-called 
"chronic mononucleosis". Surely the latest findings 
on  CAEBV have reduced  the  diagnostic  value of 
the high titer of antibodies, while have increased the 
role  of  an  high  EBV  load  in  PBMCs  of  these
patients (> 2.5 copies / μg EBVDNA) in terms of 
diagnosis, prognosis and response to therapy.
64
Therefore, the simple presence of EBV-DNA in 
plasma may have also the significance of a CAEBV 
infection since plasma of healthy subjects does not 
usually contain EBV-DNA.
b) Chronic  fatigue  syndrome  (CFS): Chronic 
fatigue  syndrome  (CFS)  is  a  new  name  for  a 
centuries’old  disorder  characterized  by  chronic 
fatigue and multiple somatic symptoms. Syndromes Medit J Hemat Infect Dis 2010; 2(1): Open Journal System
Table 7. National Institute of Allergy and Infectious Diseases/National Institute of Mental Health’s modifications of the Centers for 
Disease Control’s case definition of the chronic fatigue syndrome (from Klonoff  
73).
Exclusion
I. Psychiatric disorders
A. Psychoses
1. Psychotic depression
2. Bipolar disorder
3. Schizophrenia
B. Substance abuse
II. Postinfectious fatigue (must include A, B and C)
A. Establishment of a definite etiology
B. An etiologic agent known to regularly produce chronic active infection
C. A clinical picture compatible with ongoing active infection
1. Chronic hepatitis B or C with active liver disease
2. Infection with human immunodeficiency virus
3. Lyme disease (inadequately treated)
4. Tuberculosis
Inclusion (in patients who otherwise meet the Centers for Disease Control’case definition)
I. Fibromyalgia
II. Postinfectious fatigue
A. Lyme disease with persistent fatigue after appropriate antibiotic therapy
B. Brucellosis with persistent fatigue after appropriate antibiotic therapy
C. Acute infectious mononucleosis (documented) followed by chronic debilitating fatigue
D. Acute cytomegalovirus infection
E. Acute toxoplasmosis (adequately treated)
III. Nonpsycotic depression
IV. Somatoform disorders
V. Generalized anxiety disorder/panic disorder
resembling CFS in the eighteenth, nineteenth, and 
early twentieth centuries were known as febricula, 
neurasthenia  and  Da  Costa’s  syndrome, 
respectively.
65  In  the  1920s  through  1950s,  many 
such cases were attributed to chronic brucellosis.
66 
As  mentiones,  in  the  mid-1980s,  at  least  four 
reports described a syndrome consisting of fatigue, 
multiple somatic complaints, and elevated antibody 
titers to Epstein–Barr viral antigens 
30, 31, 32, 33. Many 
chronically  fatigued  patients  were  subsequently 
diagnosed  as  having  ”chronic  EBV  disease”, 
”chronic  EBV  syndrome”,  or  “chronic 
mononucleosis”.
35
In 1987 the Division of Viral Diseases of the 
CDC  (Atlanta,  USA)  called  a  meeting  for 
investigators and clinicians to develop a consensus 
on the features of the chronic EBV syndrome. The 
group doubted that EBV infection and the symptom 
complex known as “chronic EBV syndrome” were 
causally related. Therefore chronic EBV syndrome 
was renamed as “chronic fatigue syndrome” and a 
case definition of this syndrome was devised (Table 
6).
67
At  a  workshop  of  the  National  Institute  of 
Allergy and Infectious Diseases (NIAID) in 1991, 
the CFS case definition was modified by excluding 
specific  psychiatric  diagnoses  and  types  of  post-
infectious  fatigue  and  including  selected 
confounding  diagnoses  that  overlap  with  CFS 
(Table 7).
In  1994  the  International  CFS  Study  Group, 
coordinated  by  the  American  CDC,
68 proposed  a 
further revision of the previous CFS case definition  
of 1988, receiving notable. According to the latter 
case  definition,  the  still  more  accepted,  CFS  is 
defined  as  a  syndrome  characterized  by  the 
presence, for at least six months, of a severe fatigue, 
persistent  and/or  recurrent,  with  recent  or  well 
defined onset, not derived from excessive physical 
activity, not relieved with rest and that results in a 
substantial  reduction  in  previous  levels  of  daily 
activities  (school,  work,  social  or  personal).  To 
confirm such diagnosis, there must be associated at 
least four of the following symptoms, not existing 
prior  to  the  onset  of  fatigue  and  persistent  or 
recurrent for six months or more: 
1) short-term  memory  and/or  concentration 
impairment; 
2) sore throat; 
3) tenderness of the cervical and/or axillary lymph 
nodes;
4) myalgias; 
5) polyarthralgias  (without  any  sign  of 
inflammation); 
6) headache  with  characteristics  previously 
unusual;Medit J Hemat Infect Dis 2010; 2(1): Open Journal System
Figure 1. Classification of fatigue (Fukuda et al
  68).
7) unrefreshed sleep; 
8) malaise for more than 24 hours after exercise. 
One  of  the  merits  of  the  systematization 
proposed by CDC in 1994 was to have placed the 
CFS  among  other  forms  of  chronic  or  prolonged 
fatigue, where a diagnosis of CFS is still compatible 
with  some of  them  when  there  is  an  overlapping 
(e.g.:  fibromyalgia  syndrome  and  reactive 
depression)  (Figure  1),  while  CFS  must  be 
excluded if others forms are present as established 
by  the  exclusion  criteria  listed  in  the  table  7. 
Moreover,  the  revised  case  definition  of  1994 
allowed  the  collection  of  more  reliable 
epidemiological data: the prevalence of CFS varies 
from 2.3 to 7.4 per 100,000 persons > 18 years of 
age in 4 surveillance studies in the USA;
69 it climbs 
to 560 cases per 100,000 in Britain
70 and finally to 
37 and 127 cases respectively in Australia and New 
Zealand.
71
The  most  affected  age  is  between  20  and  40 
years, the female is represented as a ratio F/M = 2-
3/1. 
The  diagnosis  of  CFS  is primarily  a  clinical 
diagnosis, based on symptoms as listed in the most 
recent case definition. The severity of the disease 
may  vary  from  subject  to  subject  and  the  more 
severe stages are usually observed in early phases 
of  the  illness.
72 The  course  is  characterized  by 
alternating  phases  of  remission  and 
reactivation.
72,73,74 The  prognosis  remains 
favourable,  unlikely  the  disease  is  progressive, 
particularly in those forms characterized by an acute 
onset  or  with  a  less  presence  of  psychiatric 
symptoms.
74,75 To  date,  the  natural  history  of  the 
syndrome  is  still  poor  unknown,  neither  it  is 
possible to predict its clinical course, nor to identify 
any specific risk factors associated with it, such as 
an increased risk of malignancies.
75, 77
Since the diagnosis of CFS is yet a diagnosis of 
exclusion, it is worth to underline the importance of 
the exclusion of a primary depression. In particular, 
it  is  important  that  primary  depression  must  be 
distinguished  from  reactive  and  not  psychogenic 
depressive  syndromes, often associated with  CFS, 
and  considered  compatible  with  CFS  diagnosis. 
Even  somatoform  disorders  do  not  exclude  the 
diagnosis  of  CFS,  although  the  still  insufficient 
knowledge  about  the  neurobiological  bases  of 
fatigue have often led in  the past to  consider the 
syndrome in the same way as a somatization. It was 
discussed  at  length,  in  fact,  if  fatigue  must  be 
numbered among the somatoform disorders, which 
are also much more frequent in patients who meet 
the  case  definition  of  CFS  compared  to  other 
clinical conditions characterized by fatigue. There is 
no doubt that the diagnostic misclassification with 
primary  depression  and  somatoform  disorders 
accounted for and is the main obstacle to overcome 
to ensure the specificity of the syndrome
78. It will 
not be probably resolved until it will be more light
General population
Overlapping disorders 
(depressive syndrome, 
fibromyalgia)
Prolonged fatigue 
CFS
I Id di io op pa at th hi ic c c ch hr ro on ni ic c
f fa at ti ig gu ue e
Unclear chronic fatigue
and clinically evidentMedit J Hemat Infect Dis 2010; 2(1): Open Journal System
Table 8. Diagnostic criteria (adults) for CFS-like illness 1988-2003 (from Vance 
80).
- US Centers for Disease Control and Prevention (CFS – Holmes et al, 1988).
- London (ME – Dowsett et al, 1990).
- Australia (CFS- Lloyd et al, 1990).
- World Health Organization, 1994 (non clinical).
- US Centers for Disease Control and Prevention (CFS – Fukuda et al, 1994).
- “Canadian” expert consensus clinical case definition for ME/CFS (Carruthers et al, 2003).
Previous literature:
- Epidemic neuromyasthenia (Parish et al, 1978)
- Myalgic encephalomyelitis (Acheson, 1959)
- Epidemic neuromyastenia (Henderson and Shelokov, 1959)
on  the  pathogenetic  mechanism/s  of  fatigue  that 
occurs  in  many  organic  diseases,  but  also  in 
psychiatric syndromes such as primary depression 
or in the CFS as currently defined. For this reason 
the  following  CFS  case  definitions,  such  as  the 
recent  Canadian  one,
79 on  the  basis  of  clinical 
experiences with very large numbers of patients, are 
still  hardly  employed  in  clinical  and  research 
practice (see Table 8).
80
The studies so far carried out, including the our 
ones conducted at the Reference Center for CFS at 
the  Clinic  of  Infectious  Diseases  of  Chieti 
University  (Italy),  suggest  that  CFS  is  a 
heterogeneous,  probably  multifactorial 
disease.
81,82,83,84,85,86 It  could  also  include  different 
diseases from an etio-pathogenetic point of view but 
showing the same symptoms. 
The  most  accepted  pathogenic  hypothesis 
suggests the intervention in the syndrome onset of 
different factors that can interact with each other, 
although  not  all  always  present  in  the  same 
patient.
82,83,85,86 They  are  represented  by  latent 
and/or  chronic  infections,  immune  and/or 
neuroendocrine  dysfunctions,
87,88,89 environmental 
and/or  food  toxins,
90,91,92 psychological  and 
behavioural factors(Figure 2).
93,76
Among  the  triggering  events  in  individuals 
showing  a  probable  genetic  predisposition,  the 
infectious agents, particularly the viral ones, seem 
to play a crucial role, even because their persistence 
could be also responsible for the immune alterations 
reported  in  CFS  as  well.
87,88 Then,  the  immune 
alterations should facilitate the reactivation of latent 
infections, so  to  maintain in  turn  a vicious  circle 
that,  through  a  chronic  activation  of  the  immune 
system, is one of the most accredited pathogenetic 
substrates  for  the  persistence  of  a  condition  of 
chronic fatigue and/or related symptoms.
82
The  infectious  (or  post-viral)  pathogenic 
hypothesis is justified not only by the description of 
outbreaks caused by viral agents,
94,95,96,97 but also 
by  the  relative  frequency  in  CFS  patients  of 
infectious symptoms at the onset of the disease. In 
some  cases  they  are  well  characterized  infections 
(chickenpox,  rubella,  infectious  mononucleosis  or 
other  herpesvirus  infections  from  CMV,  HHV-6, 
etc.);  more  often  the  symptomatology  is 
nonspecific,  flu-like  type,  with  sore  throat,  fever, 
muscle aches, diarrhea, etc.
35,3,72
Among the  potential  viruses  involved  in  CFS 
onset,  EBV  is  primarily  because,  as  mentioned 
above, the syndrome was initially described in the 
‘80s in patients with serological signs of a chronic 
or persistent EBV infection.
30,32,33 However, even in 
the  so-called  “Lake  Tahoe”  outbreak  occurred  in 
Nevada  (USA),
98,35 the  American  epidemiologists 
have  been  unable  to  exclude  the  possibility  that 
high levels of anti-EBV antibodies in CFS cases, on 
which  the  causative  correlation  was  based,  could 
represent only the epiphenomenon of a polyclonal 
activation  of  B  lymphocytes,  as  demonstrated  by 
the concomitant presence of higher antibody levels 
compared with controls, even against other viruses 
(CMV, HSV1 and 2, measles virus ).
35,15
Another potential virus related to CFS onset is 
HHV-6, described for the first time right at the time 
of  the  Lake  Tahoe  outbreak,  and  immediately 
suspected  of  a  possible  link  with  the  epidemic 
cluster
99 and then with CFS. In particular, in respect 
of a possible etiopathogenetic link between HHV-6 
and  CFS  onset,  many  studies  were  subsequently 
report.
100 Chapenko  et  al.
101 recently  found  a 
significantly  higher  prevalence  of  persistent/latent 
HHV6  infections  and  dual  HHV6  and  HHV7 
infections among patients with CFS.
In a recent study Hickie et al.
102 demonstrated 
that CFS is a fairly common sequel of several types 
of viral and non viral infections including EBV, Q 
fever  and  Ross  River  virus.  This  work  confirms 
previous  findings  that  the  severity  of  the  acute 
illness rather than the infective pathogen appearedMedit J Hemat Infect Dis 2010; 2(1): Open Journal System
Figure 2. CFS: Pathogenesis 
to  be  the  critical  determinant  of  post-infective 
fatigue syndrome.
103
Similar evidences seem to support a causal role 
of other microrganisms in CFS pathogenesis, such 
as  enteroviruses
104,105,106    and  gram-negative 
enterobacteria.
107 In  addition,  more  recently  the 
paper  of  Lombardi  et  al.
108 published  on  Science
journal has excited a big sensation since it showed 
in 67% of CFS examined patients the presence of a 
retrovirus  related  to,  but  different  from,  known 
xenotropic  murine  leukemia  virus  (XMRV). 
However, since at least other three studies did not 
support  this  finding,
109,110,111 the  following 
hypotheses have been advanced:
1) the distribution of XMRV could be much lower 
in  Europe  than  in  USA  and  CFS  may  have 
varied environmental triggers in different parts 
of the world;
2) more  different  sequences  of  XMRV could  be 
present than previously reported and the primer 
sequences employed in different studies could 
be not exact;
3) the  replication  rate  for  XMRV  could  be  very 
low and/or the levels could fluctuate over time 
in  a  given  individual;  in  such  cases  a  single 
round  PCR  of  genomic  DNA  isolated  from 
PBMCs might not result in the amplification of 
XMRV, even from an infected individual.
Independently  from  the  inclusion  of  this  new 
virus in the very numerous directory of infectious 
agents potentially implied in CFS pathogenesis, in 
the  clinical  history  of  some  CFS  patients  the 
timeline between the infection and the onset of the 
syndrome is so obvious and well documented that it 
is hard to deny at the first such a role in triggering 
the  second.  This  is  particularly  true  for  the 
infections caused by the herpesviruses (mainly by 
EBV),  which  seems  to  have  an  important 
pathogenetic role for at least a substantial subset of
patients with CFS. 
Independently of a role of viral infection in CFS 
onset  or  during  the  course  of  the  same,  the 
assumption on which most are working is that the 
pathogenic substrate of fatigue may be the same. 
A  growing  role  has  been  attributed,  by  some 
years  to  now,  to  the  oxidative  damage  which, 
according to the Pall’s hypotheses,
112 derives from 
the release of pro-inflammatory cytokines induced 
by the trigger factor (viral infection and not only). 
The cytokines would activate the inducible form of 
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nitric oxide synthase (i NOS) and then stimulate the 
production  of  nitric  oxide  which,  in  turn,  would 
interact  with  other  reactive  substances,  such  as 
superoxide  anion,  to  lead  to  the  production  of  a 
highly  reactive  compound  as  peroxynitrite 
(OONO). A reduced oxidative metabolism with an 
increased  production  of  lactic  acid  had  been 
previously shown by our group
113 in skeletal muscle 
of  CFS  patients.  In  addition,  Australian 
researchers
114 found higher blood levels of markers 
of  oxidative  damage  in  patients  with  CFS,  well 
related to the clinical expression of CFS symptoms. 
A  significant  increase  in  circulating  levels  of 
markers  of  oxidative  damage  (T-BARS)  and  an 
equally significant reduction in the duration of lag-
phase and vitamin E levels were also found by our 
group
115 both in plasma and in LDL in patients with 
CFS  compared  with  controls.  The  potential 
consequences of these observations in a therapeutic 
way are obvious as, for example, the administration 
of  vitamin  E  would  be  able  to  correct  the  so 
observed blood alterations. The clinical trial that we 
are performing will allow us to assess whether both 
the  oxidative  stress  can  be  resolved  at 
neuromuscular level by this or other anti-oxidants, 
and  the  alteration  of  membrane  lipids  can  be 
modified,  for  example  by  a supplementation  with 
unsatured fatty acids, which also were effective in 
the only controlled trial so far conducted on CFS
116.
The  purposes  of  this  review  on  the  potential 
role  of  EBV  in  CFS  onset  do  not  include  the 
analysis  of  the  new  studies  that,  in  the  past  few 
years,  have  confirmed  the  role  of  the  oxidative 
damage  potentially  triggered  from  the  infectious 
agent
114,117,118,119,120,121 and  of  the  activation  of  the 
immune  system  directly  induced  by  the  latent 
infection or the oxidative stress.
122 New horizons in 
the pathogenesis  of  CFS  come from the  genomic 
and the proteomic that showed: a dysregulation of 
mithocondrial  and  ion  channel  regulatory  genes, 
upregulation of proinflammatory cytokine pathways 
and  different  patterns  of  endocrine,  immune  and 
metabolic dysregulation that identified as many six 
subgroups of CFS. Although the investigators could 
not identify a definitive genetic markers for CFS, 
they  were  able  to  identify  28  single  nucleotide 
polymorphism  to  predict  with  76%  accuracy 
whether an individual had CFS
122. In particular, a 
study  by  Vernon  et  al.
123 described  alterations  in 
gene transcripts among patients with post-infective 
fatigue following acute infection with EBV. They 
found that the patients which developed the post-
infective  fatigue  syndrome  had  gene  expression 
profiles  that  indicated  an  altered  host  response 
during  acute episode  of  IM when  compared  with 
those patients who have recovered without event.
In conclusion, although there are no compelling 
data to suggest that the CFS commonly results from 
chronic infection, it is tempting to consider that a 
subset  of  patients  possesses  mild,  chronic  EBV 
infection,  primarily  patients  in  whom  the  illness 
clearly  began  with  a  primary  EBV  infection  or 
those  in  whom  antibodies  to  EBNA  proteins  are 
deficient. 
Although numerous observational data support 
this  thesis  since  a  chronic  reactivation  of  latent 
infections  has  been  often  documented  in  CFS 
patients  by  determining  with  the  PCR  technique 
viral  nucleic  acids  both  in  blood  and  tissues, 
particularly  of  EBV,  it  is  more  appropriate  and 
satisfying, however, to speculate that the syndrome 
represents  a  general  response  to  a  variety  of 
psychological,  physical,  chemical,  immunological 
and virological irritants. 
The  experience  of  other  systemic  and 
nonspecific effects of the body's response to acute 
or chronic reactivated infections, and in particular 
the release of potent lymphokines and mediators of 
inflammation,  may  be  considered  the  piece  that 
unifies the various pathogenic theories, along with 
oxidative  damage  which  could  be  a  legitimate 
consequence of them at tissue level. 
Even if the pathogenic role of a chronic EBV 
infection in a number of CFS patients is probable, 
there  is  no  doubt  that  it  should  be  distinguished 
from  much  more  rare  CAEBV  cases,  and  in 
particular  the  more  severe  ones,  because  of 
significant  differences  in  symptomatic  and 
prognostic type.
Chronic Hepatitis EBV-Related
A liver involvement by EBV is always present 
in  the  acute  onset  of  infection  (IM)  and  is 
characterized  by a transient, self-limited elevation 
of liver enzymes.
124 In about 5-7% of cases jaundice 
may  be  the  presenting  symptom  together  with  a 
prominent cholestatic picture.
125,126 Severe hepatitis 
is infrequent at the time of primary EBV infection 
of immunocompetent subjects.
127,128
Some  cases  of  autoimmune
129,130 or 
granulomatous
131 hepatitis  have  also  been 
associated with EBV infection.
Liver damage during the acute EBV infection is 
hard to understand since the virus does not seem to 
be able to infect hepatocytes.
132 These cells could be 
affected indirectly by mediators that are released in 
the  liver  as  a  consequence  of  the  cytotoxic  T 
lymphocyte attack against B lymphocytes infiltrated 
in the liver parenchyma and infected by the virus.
132Medit J Hemat Infect Dis 2010; 2(1): Open Journal System
If this or another mechanism of hepatotoxicity can 
be  present  also  in  the  chronic  and/or  latent  EBV 
infection  following  the  acute  phase,  supporting  a 
possible  EBV  chronic  liver  disease,  remains  a 
problem not yet well defined, due to the rarity of 
reports of EBV-related chronic hepatitis, described 
at  most  among  the  clinical  manifestations  of 
CAEBV and in particular of severe CAEBV.
133,134
Through the evaluation of liver biopsies of 21 
patients who were positive for EBV-DNA with in 
situ  hybridization,  Drebber  et  al.
135 made  a 
diagnosis of acute hepatitis in 10 cases, of subacute 
hepatitis in 3 and chronic hepatitis in 7; in one case 
there  was  a  chronic  cholangitis  at  the  histologic 
examination. At liver biopsies evaluation of patients 
with "cryptogenic chronic hepatitis" the search for 
EBV-DNA was positive in 7 out of 68 (10,3%). In 
these  cases,  however,  it  remains  unclear  whether 
EBV-DNA positivity in the liver was suggestive for 
an  etiopathogenetic  relationship,  or  simply  an 
epiphenomenon  of  possible  reactivation  of  latent 
EBV infection. It is noteworthy, however, that the 
same AA. did not found any presence of EBV-DNA 
in liver biopsies of 20 patients with liver steatosis.
In  recent  literature  always  limited  reports  of 
EBV-related  chronic  hepatitis  appeared.
136 These 
Authors argue that chronic liver disease may be the 
only  clinical  manifestation  of  chronic  EBV 
infection when characterized by persistent low viral 
replication  or  by  frequent  reactivations.  Liver 
damage seems to be indirect, possibly linked to the 
action  of  cytotoxic  TCD8+  lymphocytes 
specifically activated by EBV and of the cytokines 
induced by such activation. 
If  an  albeit  limited  etiopathogenetic  role  in 
cryptogenic  chronic  liver  disease  seems  to  be 
recognized  for  EBV,  this  remains  difficult  to  be 
demonstrated with the current available techniques. 
Furthermore,  the  possible  role  of  EBV  in 
hepatocellular carcinogenesis (HCC) is even more 
uncertain,  although  EBV-DNA  was  detected  in 
samples of HCC with the techniques of molecular 
biology, often along with DNA of other oncogenic 
viruses (HBV and HCV).
137 A co-carcinogenic role 
also for hepatic tumors can not be yet excluded. 
Neurological EBV infections
In a surveillance study performed in Japan from 
1989  to  1991,  the  incidence  of  EBV  encephalitis 
was 0.5 cases per million persons per year.
138 So, 
EBV-associated  neurological  syndromes  represent 
rare complications in infectious mononucleosis, and 
include  acute  encephalitis,  meningitis,  acute 
disseminated  encephalomyelitis  (ADEM), 
cerebellitis and myelitis.
Within  these  complications,  prolonged  or 
relapsing  forms  have  been  described  and,  in 
according to specific serological tests for EBV, they 
seem  to  be  associated  with  chronic  EBV 
infection.
139,140,141 These neurological complications 
seem to  well  respond  to  steroid therapy and thus 
they must be considered of a post-infective type.
Since  many  reports  of  neurological 
complications  during  chronic  EBV  infections 
characterized  by  a  prolonged  or  relapsing  course 
come mainly from Japan, it seems that they must be 
included  among  clinical  pictures  of  CAEBV,  and 
particularly of the severe forms. 
However,  since  EBV  certainly  shows  a  good 
neurotropism, EBV-DNA must be looked for both 
in cerebrospinal fluid and tissues in all neurological 
forms  of  unknown  etiology,  especially in  ADEM 
and  in  those  forms  characterized  by  a  chronic 
and/or  relapsing  course.  The  same  EBV 
neurotropism could be involved both in outbreaks 
of myalgic encephalomyelitis, so described before 
that  the  new  case  definition  of  "chronic  fatigue 
syndrome" would allow a more precise framework, 
and in cases of CFS that show more similarities in a 
clinical point of view with infectious and especially 
post-infective diseases of CNS.
Conclusions
In conclusion, the dilemma of clinical forms of 
chronic EBV infection is far from be resolved. 
Since  there  is  a  wide  variety  of  clinical 
syndromes with which the persistent and/or chronic 
and/or latent EBV infection has been linked, it is 
extremely  difficult  to  identify  a  univocal 
pathogenetic link. 
Furthermore, the well studied and documented 
correlation  between  this  virus  and  oncogenetic 
events certainly does not facilitate the task. Hence 
the need to distinguish these events from those that 
are  implied  with  organ  manifestations,  neuro-
endocrine  syndromes  and/or  post-infective  sense. 
For  the  latter,  like  the  oncogenetic  events,  it  is 
likely that a crucial role is played by predisposing 
characteristics  - such  as  "genetic"  and/or 
"environmental"  ones  – of  the  host,  although  a 
causal role of eventual EBV mutant strains can not
be excluded. 
Since  the  EBV  infection  is  a  latent  infection 
characterized by more or less frequent reactivations, 
which  are  in  turn  conditioned  by  genetic  and 
environmental factors, an important role should be 
played by the very different latency programs, that 
have been widely studied in the context of EBV-
related cancer events and that would deserve to be 
examined  thoroughly  in  their  aspects  and  their Medit J Hemat Infect Dis 2010; 2(1): Open Journal System
consequences, even in the chronic complications of 
EBV infection or presumed such.
It is not a case that genomic and proteomic in 
the past few years represent the field of productive 
studies  in  the  within  of  the  research  on  “chronic 
fatigue syndrome” and on its relationships with the 
chronic infection from EBV or  from other  causal 
agents  of  latent  or  persistent  infections, viral  and 
not only viral.
142,143,144,145,146,123,147,148,149,150
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